This compound, known as Donepezil, is a reversible acetylcholinesterase inhibitor primarily used in the treatment of mild to moderate Alzheimer's disease dementia. It works by increasing acetylcholine levels in the brain, thereby enhancing cholinergic neurotransmission and improving cognitive symptoms such as memory and thinking. The unique structure featuring a 5,6-dimethoxy-2,3-dihydroinden-1-one core linked to a 1-benzylpiperidine moiety contributes to its selectivity for brain acetylcholinesterase over butyrylcholinesterase, improving efficacy and reducing peripheral side effects. It is also investigated for potential neuroprotective effects in other neurodegenerative conditions, though its primary application remains in Alzheimer's therapy.